Dr. Xavier Leleu (Centre Hospitalier Universitaire-Poitiers, France) explains the results of the Phase 2 Study IFM 2018-02 (I-Dara) in elderly frail relapsed/refractory multiple myeloma (RRMM) patients. #asco2022
Abstract Title:
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail relapsed/refractory multiple myeloma (RRMM) patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
What is the purpose of this trial?
The aim of this phase 2 study is to evaluate the efficacy and tolerability of ixazomib-daratumumab (I-Dara) without dexamethasone in elderly frail patients with relapsed/refractory multiple myeloma (RRMM).
Conclusion:
In this elderly frail population, ixazomib-daratumumab (I-Dara) is a feasible combination with favorable efficacy profile even in lenalidomide RRM and HR cytogenetic patients. Early toxicity remains a concern in this population, even though more manageable with subcutaneous daratumumab.
Clinical trial information: NCT03757221
Doctor Bio:
Dr. Xavier Leleu is Professor, Head of the Myeloma Clinic and Head of the Department of Haematology at Hôpital La Mileterie, part of the academic hospital of Poitiers (Centre Hospitalier Universitaire) in Poitiers, France.
_______________
Improving Lives | Finding the Cure
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: / imfmyeloma
Visit our website at: www.myeloma.org
Find us online:
Facebook: @myeloma | / myeloma
Twitter: @IMFMyeloma | / imfmyeloma
Instagram: @imfmyeloma | / imfmyeloma
LinkedIn: / international-myeloma-...
Support the IMF! bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard KZitem License
In most cases, captions are autogenerated by KZitem.
Негізгі бет Dr. Xavier Leleu Discusses Phase 2 Study IFM 2018-02 (I-Dara) in Elderly Frail RRMM Patients
Пікірлер